Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia.
Hu EY, Do P, Goswami S, Nunes J, Chiang CL, Elgamal S, Ventura AM, Cheney C, Zapolnik K, Williams E, Mani R, Frissora F, Mo X, Waldmeier L, Beerli RR, Peng H, Rader C, Long M, Grawunder U, Byrd JC, Muthusamy N. Hu EY, et al. Among authors: long m. Blood Adv. 2021 Aug 24;5(16):3152-3162. doi: 10.1182/bloodadvances.2020003276. Blood Adv. 2021. PMID: 34424320 Free PMC article.
Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivity.
Chiang CL, Hu EY, Chang L, Labanowska J, Zapolnik K, Mo X, Shi J, Doong TJ, Lozanski A, Yan PS, Bundschuh R, Walker LA, Gallego-Perez D, Lu W, Long M, Kim S, Heerema NA, Lozanski G, Woyach JA, Byrd JC, Lee LJ, Muthusamy N. Chiang CL, et al. Among authors: long m. Cell Rep. 2022 Jul 19;40(3):111115. doi: 10.1016/j.celrep.2022.111115. Cell Rep. 2022. PMID: 35858552 Free article.
Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia.
Heerema NA, Muthusamy N, Zhao Q, Ruppert AS, Breidenbach H, Andritsos LA, Grever MR, Maddocks KJ, Woyach J, Awan F, Long M, Gordon A, Coombes C, Byrd JC. Heerema NA, et al. Among authors: long m. Haematologica. 2021 Jun 1;106(6):1608-1615. doi: 10.3324/haematol.2018.212571. Haematologica. 2021. PMID: 32414849 Free PMC article.
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, Cogdill AP, Gill S, Porter DL, Woyach JA, Long M, Johnson AJ, Maddocks K, Muthusamy N, Levine BL, June CH, Byrd JC, Maus MV. Fraietta JA, et al. Among authors: long m. Blood. 2016 Mar 3;127(9):1117-27. doi: 10.1182/blood-2015-11-679134. Epub 2016 Jan 26. Blood. 2016. PMID: 26813675 Free PMC article. Clinical Trial.
Ibrutinib treatment improves T cell number and function in CLL patients.
Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, Woyach JA, Caligiuri MA, Johnson AJ, Muthusamy N, Byrd JC. Long M, et al. J Clin Invest. 2017 Aug 1;127(8):3052-3064. doi: 10.1172/JCI89756. Epub 2017 Jul 17. J Clin Invest. 2017. PMID: 28714866 Free PMC article. Clinical Trial.
BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia.
Tsai YT, Lakshmanan A, Lehman A, Harrington BK, Lucas FM, Tran M, Sass EJ, Long M, Flechtner AD, Jaynes F, La Perle K, Coppola V, Lozanski G, Muthusamy N, Byrd JC, Grever MR, Lucas DM. Tsai YT, et al. Among authors: long m. Blood Adv. 2017 Oct 30;1(24):2147-2160. doi: 10.1182/bloodadvances.2017006593. eCollection 2017 Nov 14. Blood Adv. 2017. PMID: 29296862 Free PMC article.
3,371 results